Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline Insights, 2015

NEW DELHI - Aug. 6, 2015 - PRLog -- The report “Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline Insights, 2015” provide with details on the enterprises and the upcoming business opportunities related to new interventions. It comprehensively includes:

Information on 15+ pipeline drugs among which  3 in Phase III , 5 in Phase II , 3 in Phase I/II , 3 drugs in Phase I  and 4 in Pre-clinical along with the companies involved in drug development.

Highlighted Phase III drugs are: Apaziquone (EOquin) by Spectrum Pharmaceuticals, MCNA (Mycobacterium phlei Cell Wall-Nucleic Acid Complex) byTelesta Therapeutics and CG-0070 by Cold Genesys, Inc.

R&D activities and technologies used along with the pipeline molecules in development.

Stages of development of pipeline molecules.

Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

Information related to collaborations, in-licensing and out-licensing deals.

DelveInsight’s, “Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline Insights, 2015” report provides the in-depth analysis of the pipeline assets across the Non Muscle Invasive Bladder. Therefore the report on “Non Muscle Invasive Bladder” provides information on chemical technology and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.